Active	Status	Sponsor type	Region	Phase	Filter
4 Active 5 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cellgram-ED (autologous mesenchymal stem cell therapy) / Pharmicell
Cellgram-ED, NCT04594850: Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously	Recruiting	2	54	RoW	Cellgram-ED, Autologous bone marrow derived mesenchymal stem cell	Pharmicell Co., Ltd.	Erectile Dysfunction	12/25	01/26
Cellgram-CKD (allogeneic bone marrow-derived mesenchymal stem cells) / Pharmicell
NCT05042206: Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease	Completed	1	10	RoW	Cellgram-CKD	Pharmicell Co., Ltd.	Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4	09/23	09/23
NCT05096182: Long-term Follow-up of Patients With Chronic Kidney Disease Who Had Administered Cellgram-CKD in PMC-P-12 Study	Active, not recruiting	N/A	10	RoW		Pharmicell Co., Ltd.	Renal Insufficiency, Chronic	03/27	03/27
Hearticellgram-AMI (Autologous bone marrow derived mesenchymal stem cells) / Pharmicell
RELIEF, NCT01652209: To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.	Active, not recruiting	3	90	RoW	Hearticellgram-AMI, (Autologous bone marrow derived mesenchymal stem cells)	Pharmicell Co., Ltd.	Acute Myocardial Infarction	10/24	10/24
Cellgram-IPF / Pharmicell
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cellgram-ED (autologous mesenchymal stem cell therapy) / Pharmicell
Cellgram-ED, NCT04594850: Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously	Recruiting	2	54	RoW	Cellgram-ED, Autologous bone marrow derived mesenchymal stem cell	Pharmicell Co., Ltd.	Erectile Dysfunction	12/25	01/26
Cellgram-CKD (allogeneic bone marrow-derived mesenchymal stem cells) / Pharmicell
NCT05042206: Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease	Completed	1	10	RoW	Cellgram-CKD	Pharmicell Co., Ltd.	Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4	09/23	09/23
NCT05096182: Long-term Follow-up of Patients With Chronic Kidney Disease Who Had Administered Cellgram-CKD in PMC-P-12 Study	Active, not recruiting	N/A	10	RoW		Pharmicell Co., Ltd.	Renal Insufficiency, Chronic	03/27	03/27
Hearticellgram-AMI (Autologous bone marrow derived mesenchymal stem cells) / Pharmicell
RELIEF, NCT01652209: To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.	Active, not recruiting	3	90	RoW	Hearticellgram-AMI, (Autologous bone marrow derived mesenchymal stem cells)	Pharmicell Co., Ltd.	Acute Myocardial Infarction	10/24	10/24
Cellgram-IPF / Pharmicell
No trials found